{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:53:07Z","timestamp":1773841987895,"version":"3.50.1"},"reference-count":129,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Resistance to therapy and disease progression are the main causes of mortality in most cancers. In particular, the development of resistance is an important limitation affecting the efficacy of therapeutic alternatives for cancer, including chemotherapy, radiotherapy, and immunotherapy. Signaling pathways are largely responsible for the mechanisms of resistance to cancer treatment and progression, and multiple myeloma is no exception. p38 mitogen-activated protein kinase (p38) is downstream of several signaling pathways specific to treatment resistance and progression. Therefore, in recent years, developing therapeutic alternatives directed at p38 has been of great interest, in order to reverse chemotherapy resistance and prevent progression. In this review, we discuss recent findings on the role of p38, including recent advances in our understanding of its expression and activity as well as its isoforms, and its possible clinical role based on the mechanisms of resistance and progression in multiple myeloma.<\/jats:p>","DOI":"10.3390\/cancers16020256","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:21:38Z","timestamp":1704691298000},"page":"256","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Mario","family":"Morales-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, Mexican Institute of Social Security (IMSS), Mexico City 06720, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3932-2483","authenticated-orcid":false,"given":"Mario I.","family":"Vega","sequence":"additional","affiliation":[{"name":"Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, Mexican Institute of Social Security (IMSS), Mexico City 06720, Mexico"},{"name":"Department of Medicine, Hematology-Oncology and Clinical Nutrition Division, Greater Los Angeles VA Healthcare Center, UCLA Medical Center, Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1358\/dot.2013.49.09.2020941","article-title":"Contemporary drug therapies for multiple myeloma","volume":"49","author":"Azab","year":"2013","journal-title":"Drugs Today"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"289243","DOI":"10.1155\/2012\/289243","article-title":"The Roles of Mitogen-Activated Protein Kinase Pathways in TGF-\u03b2-Induced Epithelial-Mesenchymal Transition","volume":"2012","author":"Gui","year":"2012","journal-title":"J. Signal Transduct."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Lim\u00f3n, A., Joaquin, M., Caballero, M., Posas, F., and de Nadal, E. (2020). The p38 Pathway: From Biology to Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21061913"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yexmp.2019.01.009","article-title":"p38 MAP kinases: Plausible diagnostic and prognostic serum protein marker of non small cell lung cancer","volume":"107","author":"Sahu","year":"2019","journal-title":"Exp. Mol. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/MMBR.68.2.320-344.2004","article-title":"ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions","volume":"68","author":"Roux","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1128\/MCB.25.13.5466-5479.2005","article-title":"Selective activation of mitogen-activated protein (MAP) kinase kinase 3 and p38\u03b1 MAP kinase is essential for cyclic AMP-dependent UCP1 expression in adipocytes","volume":"25","author":"Robidoux","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1038\/s41388-022-02329-3","article-title":"Role of p38 MAP kinase in cancer stem cells and metastasis","volume":"41","author":"Kudaravalli","year":"2022","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1158\/0008-5472.CAN-12-2664","article-title":"p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction","volume":"72","author":"He","year":"2012","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8766","DOI":"10.1038\/sj.onc.1208118","article-title":"p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells","volume":"23","author":"Hideshima","year":"2004","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1620\/tjem.2022.J044","article-title":"Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK\/NUPR1","volume":"257","author":"Jing","year":"2022","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6096391","DOI":"10.1155\/2020\/6096391","article-title":"Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38\/MAPK and Wnt\/\u03b2-Catenin Signaling Pathways","volume":"2020","author":"Wu","year":"2020","journal-title":"Oxidative Med. Cell Longev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.12688\/f1000research.22092.1","article-title":"An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling","volume":"9","author":"Han","year":"2020","journal-title":"F1000Research"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1073\/pnas.0307075101","article-title":"Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells","volume":"101","author":"Uddin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1093\/emboj\/17.15.4426","article-title":"Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2\/p38, and may mediate activation of CREB","volume":"17","author":"Deak","year":"1998","journal-title":"EMBO J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"29661","DOI":"10.1074\/jbc.273.45.29661","article-title":"RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase under dominant control of p38\u03b1 mitogen-activated protein kinase (p38\u03b1MAPK)","volume":"273","author":"Pierrat","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/(SICI)1097-4547(20000601)60:5<623::AID-JNR7>3.0.CO;2-4","article-title":"Constitutive Activity and Differential Localization of p38 and p38 MAPKs in Adult Mouse Brain","volume":"60","author":"Lee","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1074\/jbc.273.3.1741","article-title":"Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6","volume":"273","author":"Enslen","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"31398","DOI":"10.1074\/jbc.M703857200","article-title":"p38\u03b1 antagonizes p38\u03b3 activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response","volume":"282","author":"Qi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55684","DOI":"10.18632\/oncotarget.18264","article-title":"The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells","volume":"8","author":"Corre","year":"2017","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Matesanz, N., Nikolic, I., Leiva, M., Pulgar\u00edn-Alfaro, M., Santamans, A.M., Bernardo, E., Mora, A., Herrera-Melle, L., Rodr\u00edguez, E., and Beiroa, D. (2018). p38\u03b1 blocks brown adipose tissue thermogenesis through p38\u03b4 inhibition. PLoS Biol., 16.","DOI":"10.1371\/journal.pbio.2004455"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/MCB.20.13.4543-4552.2000","article-title":"Involvement of the MKK6-p38\u03b3 cascade in \u03b3-radiation-induced cell cycle arrest","volume":"20","author":"Wang","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1515\/BC.2002.173","article-title":"In the cellular garden of forking paths: How p38 MAPKs signal for downstream assistance","volume":"383","author":"Shi","year":"2002","journal-title":"Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/BJ20100323","article-title":"Mechanisms and functions of p38 MAPK signalling","volume":"429","author":"Cuadrado","year":"2010","journal-title":"Biochem. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1126\/science.abl6324","article-title":"ZAK\u03b1-driven ribotoxic stress response activates the human NLRP1 inflammasome","volume":"377","author":"Robinson","year":"2022","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Vega, G., Aviles-Salas, A., Chalapud, J.R., Mart\u00ednez-Paniagua, M., Pelayo, R., Mayani, H., Hern\u00e1ndez-Pando, R., Mart\u00ednez-Maza, O., Huerta-Yepez, S., and Bonavida, B. (2015). P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1778-8"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.5858\/133.11.1850","article-title":"p38 Mitogen-activated protein kinase and hematologic malignancies","volume":"133","author":"Feng","year":"2009","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1091\/mbc.12.1.27","article-title":"Transforming growth factor-\u03b21 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism","volume":"12","author":"Bhowmick","year":"2001","journal-title":"Mol. Biol. Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/bcr2794","article-title":"Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway","volume":"12","author":"Mao","year":"2010","journal-title":"Breast Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41420-023-01638-0","article-title":"Tumor suppressor p53 mediates interleukin-6 expression to enable cancer cell evasion of genotoxic stress","volume":"9","author":"Phan","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"An, H., Lu, X., Liu, D., and Yarbrough, W.G. (2011). LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating p38 association with the wild-type p53 induced phosphatase 1 (WIP1). PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016427"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1128\/MCB.01205-10","article-title":"Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes","volume":"31","author":"Pillai","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/372739a0","article-title":"A protein kinase involved in the regulation of inflammatory cytokine biosynthesis","volume":"372","author":"Lee","year":"1994","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10531","DOI":"10.1073\/pnas.92.23.10531","article-title":"Mxi2, a mitogen-activated protein kinase that recognizes and phosphorylates Max protein","volume":"92","author":"Zervos","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1006\/bbrc.2002.6529","article-title":"Exip, a new alternative splicing variant of p38\u03b1, can induce an earlier onset of apoptosis in HeLa cells","volume":"291","author":"Sudo","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, P., Yu, P., Gao, P., Shi, T., and Ma, D. (2009). Discovery of novel human transcript variants by analysis of intronic single-block EST with polyadenylation site. BMC Genom., 10.","DOI":"10.1186\/1471-2164-10-518"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.4049\/jimmunol.174.11.7257","article-title":"Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils","volume":"174","author":"Lominadze","year":"2005","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1074\/jbc.270.13.7420","article-title":"Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine","volume":"270","author":"Raingeaud","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.4049\/jimmunol.173.6.3979","article-title":"Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression","volume":"173","author":"Mahlknecht","year":"2004","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng1285","article-title":"Complete sequencing and characterization of 21,243 full-length human cDNAs","volume":"36","author":"Ota","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Collins, J.E., Wright, C.L., Edwards, C.A., Davis, M.P., Grinham, J.A., Cole, C.G., Goward, M.E., Aguado, B., Mallya, M., and Mokrab, Y. (2004). A genome annotation-driven approach to cloning the human ORFeome. Genome Biol., 5.","DOI":"10.1186\/gb-2004-5-10-r84"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/jmcc.2001.1523","article-title":"Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member, stress-activated protein kinase-3 (SAPK3)","volume":"34","author":"Court","year":"2002","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1073\/pnas.93.9.4355","article-title":"ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation","volume":"93","author":"Lechner","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1101\/gr.2596504","article-title":"The status, quality, and expansion of the NIH full-length cDNA project: The Mammalian Gene Collection (MGC)","volume":"14","author":"Gerhard","year":"2004","journal-title":"Genome Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1093\/emboj\/17.12.3372","article-title":"PRAK, a novel protein kinase regulated by the p38 MAP kinase","volume":"17","author":"New","year":"1998","journal-title":"EMBO J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/10428194.2018.1516286","article-title":"Cytotoxic effect caspase activation dependent of a genetically engineered fusion protein with a CD154 peptide mimetic (OmpC-CD154p) on B-NHL cell lines is mediated by the inhibition of bcl-6 and YY1 through MAPK p38 activation","volume":"60","author":"Vega","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/MCB.19.1.21","article-title":"Regulation of the MEF2 family of transcription factors by p38","volume":"19","author":"Zhao","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1128\/MCB.19.6.4028","article-title":"Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors","volume":"19","author":"Yang","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.fsi.2015.09.018","article-title":"Gene structure, molecular characterization and transcriptional expression of two p38 isoforms (MAPK11 and MAPK14) from rock bream (Oplegnathus fasciatus)","volume":"47","author":"Umasuthan","year":"2015","journal-title":"Fish Shellfish Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1039\/C4MB00511B","article-title":"Prioritizing candidate disease-related long non-coding RNAs by walking on the heterogeneous lncRNA and disease network","volume":"11","author":"Zhou","year":"2015","journal-title":"Mol. BioSyst."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1002\/jcp.27547","article-title":"Emerging roles of noncoding RNAs in multiple myeloma: A review","volume":"234","author":"Yang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_55","first-page":"589","article-title":"YY1-Activated Long Noncoding RNA SNHG5 Promotes Glioblastoma Cell Proliferation through p38\/MAPK Signaling Pathway","volume":"34","author":"Chen","year":"2019","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mar\u00edn-B\u00e9jar, O., Marchese, F.P., Athie, A., S\u00e1nchez, Y., Gonz\u00e1lez, J., Segura, V., Huang, L., Moreno, I., Navarro, A., and Monz\u00f3, M. (2013). Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. Genome Biol., 14.","DOI":"10.1186\/gb-2013-14-9-r104"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1586\/14737159.2014.946906","article-title":"The potential of miRNAs as biomarkers for multiple myeloma","volume":"14","author":"Rocci","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10142-016-0519-7","article-title":"Integrative analysis of signaling pathways and diseases associated with the miR-106b\/25 cluster and their function study in berb erine-induced multiple myeloma cells","volume":"17","author":"Gu","year":"2017","journal-title":"Funct. Integr. Genom."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"588","DOI":"10.5114\/aoms.2017.68757","article-title":"MicroRNA-141 inhibits proliferation of gastric cardia adenocarcinoma by targeting MACC1","volume":"14","author":"Li","year":"2018","journal-title":"Arch. Med. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ng2033","article-title":"p38\u03b1 suppresses normal and cancer cell proliferation by antagonizing the JNK\u2013c-Jun pathway","volume":"39","author":"Hui","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","article-title":"Pathological roles of MAPK signaling pathways in human diseases","volume":"1802","author":"Kim","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000438641","article-title":"The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment","volume":"38","author":"Gao","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-0348-8012-1_2","article-title":"Potential of p38 MAP kinase inhibitors in the treatment of cancer","volume":"60","author":"Schultz","year":"2003","journal-title":"Prog. Drug Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1021\/jm9900570","article-title":"Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1\/cyclin B inhibition, and in vitro antitumor activity","volume":"42","author":"Schultz","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1038\/sj.onc.1207336","article-title":"Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance","volume":"23","author":"Vega","year":"2004","journal-title":"Oncogene"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15605","DOI":"10.1074\/jbc.273.25.15605","article-title":"Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket","volume":"273","author":"Gum","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-5793(95)00357-F","article-title":"SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1","volume":"364","author":"Lyu","year":"1995","journal-title":"FEBS Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1093\/emboj\/16.12.3563","article-title":"Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases","volume":"16","author":"Goedert","year":"1997","journal-title":"EMBO J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.cell.2006.03.048","article-title":"p38 and a p38-Interacting Protein Are Critical for Downregulation of E-Cadherin during Mouse Gastrulation","volume":"125","author":"Zohn","year":"2006","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2141.2007.06895.x","article-title":"P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells","volume":"140","author":"Wen","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-015-0016-z","article-title":"Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma","volume":"4","author":"Koerber","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1113\/EP088762","article-title":"Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways","volume":"106","author":"Zhang","year":"2021","journal-title":"Exp. Physiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbrc.2023.05.116","article-title":"p38 MAPK inhibitor SB203580 enhances anticancer activity of PARP inhibitor olaparib in a synergistic way on non-small cell lung carcinoma A549 cells","volume":"670","author":"Dey","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/bj3510095","article-title":"Specificity and mechanism of action of some commonly used protein kinase inhibitors","volume":"351","author":"Davies","year":"2000","journal-title":"Biochem. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.coph.2004.03.009","article-title":"The p38 MAP kinase pathway as a therapeutic target in inflammatory disease","volume":"4","author":"Saklatvala","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.irn.2020.03.001","article-title":"Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine","volume":"151","author":"Sharma","year":"2020","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Wu, Y., Duan, X., Gao, Z., Yang, N., and Xue, F. (2022). AICAR attenuates postoperative abdominal adhesion formation by inhibiting oxidative stress and promoting mesothelial cell repair. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0272928"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1021\/ml2001455","article-title":"The Discovery of VX-745: A Novel and Selective p38\u03b1 Kinase Inhibitor","volume":"2","author":"Duffy","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2002-06-1874","article-title":"Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"ref_80","first-page":"1020","article-title":"Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome","volume":"7","author":"Ding","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543776.2023.2242584","article-title":"A patent review of MAPK inhibitors (2018\u2014Present)","volume":"33","author":"Wydra","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","article-title":"Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response","volume":"16","author":"Gandhi","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1535-7163.MCT-04-0303","article-title":"8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1\/2, and Akt kinase: Role in induction of apoptosis in multiple myeloma","volume":"4","author":"Ghias","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_84","first-page":"3827","article-title":"p38\u03b1-Selective MAP Kinase Inhibitor Reduces Tumor Growth in Mouse Xenograft Models of Multiple Myeloma","volume":"28","author":"Medicherla","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.leu.2404200","article-title":"Inhibition of p38\u03b1 MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo","volume":"20","author":"Navas","year":"2006","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/0008-5472.CAN-06-4361","article-title":"Inhibition of p38\u03b1 mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma","volume":"67","author":"Vanderkerken","year":"2007","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.yexcr.2006.02.026","article-title":"Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation","volume":"312","author":"Nguyen","year":"2006","journal-title":"Exp. Cell Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood.V108.11.3580.3580","article-title":"Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM)","volume":"108","author":"Siegel","year":"2006","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2006.06443.x","article-title":"BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase\/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth","volume":"136","author":"Yasui","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_90","unstructured":"Holtzman, M.J., Romero, A.G., Gerovac, B.J., Han, Z., Keeler, S.P., and Wu, K. (2023, November 20). Mitogen-Activated Protein Kinase Inhibitors, Methods of Making, and Methods of Use Thereof. Available online: https:\/\/patents.google.com\/patent\/US11407771B2\/en."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1535-7163.MCT-13-0513","article-title":"Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity","volume":"13","author":"Campbell","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.chembiol.2023.09.013","article-title":"Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor","volume":"30","author":"Bhattacharjee","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Signorile, M.L., Grossi, V., Fasano, C., Forte, G., Disciglio, V., Sanese, P., De Marco, K., La Rocca, F., Armentano, R., and Valentini, A.M. (2022). c-MYC Protein Stability Is Sustained by MAPKs in Colorectal Cancer. Cancers, 14.","DOI":"10.3390\/cancers14194840"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2008.07044.x","article-title":"p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications","volume":"141","author":"Ishitsuka","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human Phase I Study of Copanlisib (BAY 80-6946), an Intravenous Pan-Class I Phosphatidylinositol 3-kinase Inhibitor, in Patients with Advanced Solid Tumors and non-Hodgkin\u2019s Lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/leu.2012.71","article-title":"Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma","volume":"26","author":"Yang","year":"2012","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/bioinformatics\/btu133","article-title":"Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach","volume":"30","author":"Peng","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/mp.55.5.273","article-title":"Molecular aspects of multiple myeloma","volume":"55","author":"Pratt","year":"2002","journal-title":"Mol. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2002-12-3647","article-title":"Map kinase signaling pathways and hematologic malignancies","volume":"101","author":"Platanias","year":"2003","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","article-title":"Activating Mutations of N- and K-ras in Multiple Myeloma Show Different Clinical Associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial","volume":"88","author":"Liu","year":"1996","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jcp.10148","article-title":"Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1\/2)","volume":"193","author":"Zhang","year":"2002","journal-title":"J. Cell. Physiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/CAD.0000000000000068","article-title":"Crucial role of heme oxygenase-1 in the sensitivity of acute myeloid leukemia cell line Kasumi-1 to ursolic acid","volume":"25","author":"Ma","year":"2014","journal-title":"Anticancer Drugs"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/febs.13633","article-title":"Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells","volume":"283","author":"Wu","year":"2016","journal-title":"FEBS J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell\u2013derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.18632\/oncotarget.28073","article-title":"TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan","volume":"12","author":"Moen","year":"2021","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s13277-015-3832-1","article-title":"Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3389\/fonc.2019.00722","article-title":"Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma","volume":"9","author":"Guo","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2018.12.014","article-title":"Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway","volume":"444","author":"Xiao","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e1264564","DOI":"10.1080\/2162402X.2016.1264564","article-title":"p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells","volume":"6","author":"Soriani","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/2211-5463.12960","article-title":"Trifluoperazine induces cellular apoptosis by inhibiting autophagy and targeting NUPR1 in multiple myeloma","volume":"10","author":"Li","year":"2020","journal-title":"FEBS Open Bio"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1182\/blood-2008-09-179796","article-title":"Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-\u03baB with antimyeloma activity in vitro and in vivo","volume":"113","author":"Tiedemann","year":"2009","journal-title":"Blood"},{"key":"ref_113","first-page":"175","article-title":"Effect of Celastrol Based on IRAK4\/ERK\/p38 Signaling Pathway on Proliferation and Apoptosis of Multiple Myeloma Cells","volume":"30","author":"Xu","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-08-0405","article-title":"Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo","volume":"14","author":"Bhandarkar","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2015.1099645","article-title":"Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma","volume":"57","author":"Azab","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/cam4.2695","article-title":"Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models","volume":"9","author":"Stefka","year":"2020","journal-title":"Cancer Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3324\/haematol.2017.181172","article-title":"Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease","volume":"103","author":"He","year":"2018","journal-title":"Haematologica"},{"key":"ref_118","first-page":"e464","article-title":"Tumor cell p38 MAPK: A trigger of cancer bone osteolysis","volume":"2","author":"Liu","year":"2015","journal-title":"Cancer Cell Microenviron."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2141.2007.06686.x","article-title":"Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity","volume":"138","author":"Trentin","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1158\/1535-7163.MCT-16-0041","article-title":"A New Anti-CXCR4 Antibody That Blocks the CXCR4\/SDF-1 Axis and Mobilizes Effector Cells","volume":"15","author":"Broussas","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.exphem.2014.07.261","article-title":"Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways","volume":"42","author":"Pandey","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/13816128113199990638","article-title":"The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma","volume":"20","author":"Li","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1038\/srep12809","article-title":"SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cellimm.2014.03.003","article-title":"TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells","volume":"289","author":"Cho","year":"2014","journal-title":"Cell. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Abdi, J., Mutis, T., Garssen, J., and Redegeld, F. (2013). Characterization of the Toll-like receptor expression profile in human multiple myeloma cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060671"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2741\/e542","article-title":"Modulation of normal and malignant plasma cells function by toll-like receptors","volume":"4","author":"Jego","year":"2012","journal-title":"Front. Biosci. (Elite Ed.)"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Liu, Z., Li, T., Jiang, K., Huang, Q., Chen, Y., and Qian, F. (2014). Induction of chemoresistance by all-trans retinoic acid via a noncanonical signaling in multiple myeloma cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085571"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/1042819031000099652","article-title":"Effects of all-trans retinoic acid (ATRA) on human myeloma cells","volume":"44","author":"Otsuki","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cytob.21142","article-title":"Feasibility study: Phosphospecific flow cytometry enabling rapid functional analysis of bone marrow samples from patients with multiple myeloma","volume":"86","author":"Simard","year":"2014","journal-title":"Cytom. Part B Clin. Cytom."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/256\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:41:15Z","timestamp":1760103675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":129,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020256"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020256","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]}}}